Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
The efficacy of mutant IDH1 inhibition in a genetically engineered mouse model of cholangiocarcinoma is mediated by stimulation of cytotoxic T-cell function and derepression of TET2 in tumor cells, which epigenetically resensitizes tumor cells to IFNγ.